Literature DB >> 2663806

Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

R N Jones, P C Fuchs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2663806     DOI： 10.1093/jac/23.1.163

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  11 in total

1.  Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.

Authors:  O Mimoz; A Jacolot; S Leotard; N Hidri; K Samii; P Nordmann; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.

Authors:  J Martínez-Beltrán; R Cantón; J Liñares; J García de Lomas; C Gimeno; F Tubau; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

Review 3.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

4.  Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.

Authors:  Kenneth P Smith; Thea Brennan-Krohn; Susan Weir; James E Kirby
Journal:  J Clin Microbiol       Date:  2016-11-30       Impact factor: 5.948

5.  Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.

Authors:  O Mimoz; S Leotard; A Jacolot; C Padoin; K Louchahi; O Petitjean; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

Authors:  J A Washington; R N Jones; E H Gerlach; P R Murray; S D Allen; C C Knapp
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

Authors:  J Hübner; D Hartung; A Kropec; F D Daschner
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

9.  Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.

Authors:  Fred C Tenover; Shannon L Emery; Carol A Spiegel; Patricia A Bradford; Samantha Eells; Andrea Endimiani; Robert A Bonomo; John E McGowan
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

10.  In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-08       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.